The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000329.3(RPE65):c.272G>A (p.Arg91Gln)

CA226533

98857 (ClinVar)

Gene: RPE65
Condition: RPE65-related recessive retinopathy
Inheritance Mode: Autosomal recessive inheritance
UUID: 56991886-2f75-46fa-809b-e3cfde70721f
Approved on: 2024-02-20
Published on: 2024-02-20

HGVS expressions

NM_000329.3:c.272G>A
NM_000329.3(RPE65):c.272G>A (p.Arg91Gln)
NC_000001.11:g.68444857C>T
CM000663.2:g.68444857C>T
NC_000001.10:g.68910540C>T
CM000663.1:g.68910540C>T
NC_000001.9:g.68683128C>T
NG_008472.1:g.10103G>A
NG_008472.2:g.10103G>A
ENST00000262340.6:c.272G>A
ENST00000262340.5:c.272G>A
NM_000329.2:c.272G>A

Pathogenic

Met criteria codes 6
PP4_Moderate PP3 PP1 PM3_Strong PM2_Supporting PS3_Supporting
Not Met criteria codes 1
PM5

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for RPE65 Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP
NM_000329.3(RPE65):c.272G>A (p.Arg91Gln) is a missense variant that replaces arginine with glutamine at position 91 in RPE65. At least one proband harboring this variant has been genotyped by next-generation sequencing analysis of 586 candidate genes without an alternative explanation for visual impairment (2 pts), with phenotypes including congenital onset (1 pt), abnormal best corrected visual acuity test (1 pt), extinguished scotopic (0.5 pts) and photopic (1 pt) electroretinogram responses, bone spicule pigmentation (0.5 pts), white or yellow dots in the fundus (2 pts), and nystagmus (1 pt), which together are highly specific for RPE65-related recessive retinopathy (9 points, PP4_Moderate). This variant has also been reported in at least 2 probands with early-onset severe retinal dystrophy who were compound heterozygous with either the c.1022T>C (p.Leu341Ser) variant or the c.370C>T (p.Arg124Ter) variant suspected in trans (1 point, PMID: 32865313, PMID: 27102010), both of which were previously classified pathogenic by the ClinGen LCA / eoRD VCEP. This variant has also been reported in the homozygous state in at least 2 probands with early-onset severe retinal dystrophy (1 point, PMID: 32865313, PMID: 34492281; 2 total points, PM3_Strong). The variant has been reported to segregate with childhood-onset severe retinal dystrophy through a proband plus 1 similarly affected relative, both of whom harbor the variant present in the compound heterozygous state with the c.725+4A>G variant confirmed in trans (PP1; PMID: 11462243). This variant is present in gnomAD v.2.1.1 at a Grpmax allele frequency of 0.0001609, with 8 alleles / 24940 total alleles in the African / African-American population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). The computational predictor REVEL gives a score of 0.659, which is above the ClinGen LCA / eoRD VCEP threshold of ≥ 0.644 and predicts a damaging effect on RPE65 function (PP3). The variant also exhibited 1.33% enzymatic activity in a retinoid isomerase assay relative to the wild-type control, which is lower than the ClinGen LCA / eoRD PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PS3_Supporting, Table 2, PMID: 19431183). Two other missense variants encoding different amino acid substitutions at the same codon have been reported in association with RPE65-related recessive retinopathy (PMID: 17724218, PMID: 9501220). However, c.271C>T (p.Arg91Trp) and c.272G>C (p.Arg91Pro) have not yet been classified by the ClinGen LCA / eoRD VCEP, and PM5 was not considered to avoid circularity. In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PS3_Supporting, PM2_Supporting, PM3_Strong, PP1, PP3, PP4_Moderate (VCEP specifications version 1.0.0; date of approval 09/21/2023).
Met criteria codes
PP4_Moderate
At least one proband harboring this variant has been genotyped by next-generation sequencing analysis of 586 candidate genes without an alternative explanation for visual impairment (2 pts), with phenotypes including congenital onset (1 pt), abnormal best corrected visual acuity test (1 pt), extinguished scotopic (0.5 pts) and photopic (1 pt) ERG responses, bone spicule pigmentation of the fundus (0.5 pts), white or yellow dots in fundus (2 pts), and nystagmus (1 pt), which together are highly specific for RPE65-related recessive retinopathy (9 points, PP4_Moderate).
PP3
The computational predictor REVEL gives a score of 0.659, which is above the ClinGen LCA / eoRD VCEP threshold of ≥ 0.644 and predicts a damaging effect on RPE65 function (PP3).
PP1
The variant has been reported to segregate with childhood-onset severe retinal dystrophy through the proband plus 1 similarly affected relative, with the variant present in the compound heterozygous state with the c.725+4A>G variant confirmed in trans (PP1; PMID: 11462243). Two other reported probands have an affected relative with the same genotype harboring the variant in apparent compound heterozygosity, but lack confirmation that the second variant is in trans (PMID: 32865313).
PM3_Strong
This variant has been reported in at least 2 probands with early-onset severe retinal dystrophy who were compound heterozygous with either the c.1022T>C (p.Leu341Ser) variant or the c.370C>T (p.Arg124Ter) variant suspected in trans (1 point, PMID: 32865313, PMID: 27102010), both of which were previously classified pathogenic by the ClinGen LCA / eoRD VCEP. This variant has also been reported in the homozygous state in at least 2 probands with early-onset severe retinal dystrophy (1 point, PMID: 32865313, PMID: 34492281; 2 total points, PM3_Strong).
PM2_Supporting
This variant is present in gnomAD v.2.1.1 at a Grpmax allele frequency of 0.0001609, with 8 alleles/24940 total alleles in the African/African-American population, which is lower than the ClinGen LCA/eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting).
PS3_Supporting
The variant exhibited 1.33% enzymatic activity in a retinoid isomerase assay relative to the wild-type control, which is lower than the ClinGen LCA / eoRD PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PS3_Supporting, Table 2, PMID: 19431183).
Not Met criteria codes
PM5
Two other missense variants encoding different amino acid substitutions at the same codon have been reported in association with RPE65-related recessive retinopathy (PMID: 17724218, PMID: 9501220). However, c.271C>T (p.Arg91Trp) and c.272G>C (p.Arg91Pro) have not yet been classified by the ClinGen LCA / eoRD VCEP, so PM5 is not met.
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.